A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Buparlisib (Primary) ; Dactolisib (Primary) ; Capecitabine; Lapatinib; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 17 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 17 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.